Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Organisation › Details

Oxford Biomedica plc (LSE: OXB)

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. *

 

Period Start 1996-01-01 splitoff predec
  Group Oxford Biomedica (Group)
  Predecessor Oxford Biomedica Ltd.
Product Industry gene therapy
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Paynter, Stuart (Oxford BioMedica 201708– CFO before De La Rue plc + Shire Pharmaceuticals + Steris)
     
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street Windrush Court
Transport Way
  City OX4 6LT Oxford
  Tel +44-1865-783000
    Address record changed: 2018-07-24
     
Basic data Employees E: 501 to 1,000 (2020-03-18)
  Currency GBP
  Annual sales 65,000,000 (revenue, total, consolidated (2019) 2019-12-31)
  Profit 7,541,000 (2018-12-31)
  Cash 16,000,000 (2019-12-31)
     
    * Document for �About Section�: Oxford Biomedica plc. (3/18/20). "Press Release: Building the Group for Future Growth. Business Update". Oxford.
     
   
Record changed: 2020-06-08

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for Oxford Biomedica (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top